asperflavin has been researched along with isoniazid in 1 studies
| Studies (asperflavin) | Trials (asperflavin) | Recent Studies (post-2010) (asperflavin) | Studies (isoniazid) | Trials (isoniazid) | Recent Studies (post-2010) (isoniazid) |
|---|---|---|---|---|---|
| 5 | 0 | 2 | 21,815 | 960 | 4,493 |
| Protein | Taxonomy | asperflavin (IC50) | isoniazid (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 4.85 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 8.29 | |
| Putative FAD-containing monooxygenase MymA | Mycobacterium tuberculosis H37Rv | 4.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aree, T; Ganihigama, DU; Hongmanee, P; Kittakoop, P; Mahidol, C; Ruchirawat, S; Sangher, S; Sureram, S | 1 |
1 other study(ies) available for asperflavin and isoniazid
| Article | Year |
|---|---|
Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Biological Products; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrrolidines; Quinolines; Structure-Activity Relationship | 2015 |